{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-111340","form_type":"8-K","ticker":"TELA","cik":"0001561921","company_name":"TELA Bio, Inc.","filed_at":"2022-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.167782+00:00","generated_at":"2026-06-23T00:49:11.055124+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"TELA Bio publishes 24-month BRAVO study showing 2.6% recurrence rate with OviTex in hernia repair","bullets":["BRAVO study 24-month analysis published in Annals of Medicine and Surgery; 92 patients enrolled.","OviTex 1S Permanent demonstrated a 2.6% hernia recurrence rate at 24 months via open, laparoscopic, or robotic techniques.","Patient quality-of-life showed statistically significant improvement from baseline at 3, 12, and 24 months.","Surgical site occurrences in 38% of patients; 78% were high-risk (obesity, smoking, COPD, diabetes, etc.).","CEO states commitment to ongoing BRAVO II study evaluating OviTex in robot-assisted repairs."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-111340","json":"https://secwatch.observer/filing/0001104659-22-111340.json","markdown":"https://secwatch.observer/filing/0001104659-22-111340.md","text":"https://secwatch.observer/filing/0001104659-22-111340.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1561921/000110465922111340/0001104659-22-111340-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1561921/000110465922111340/tm2228895d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T00:49:11.055124+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}